Recently, treatment with anti‐receptor activator of nuclear factor kappa‐B ligand (RANKL) monoclonal antibodies and bisphosphonates was found to be potentially effective to prevent THA revision in patients with osteoporosis.19, 20. Here, TNFSF11 is linked to osteoporosis.